Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Mechanistic Comparison# Dosing Comparison# Amycretin Dosing# Amycretin dosing is investigational: Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1 Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks Phase 3 dose selection will be informed by the completed phase 2 data
The downside
RhIGF-1 is the recombinant form of insulin-like growth factor-1, and has been researched for its potential in mitigating growth hormone (GH) insensitivity
following a routine inspection of the facility when it found the company's Homeopathic Infant's Teething Tablets in violation of current good manufacturing practice (CGMP) regulations
